{
    "2021-05-20": [
        [
            {
                "time": "2023-05-20",
                "original_text": "贝达药业CTLA-4抗体联合PD-1抗体治疗晚期宫颈癌药品临床试验申请受理",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "CTLA-4抗体",
                        "PD-1抗体",
                        "晚期宫颈癌",
                        "临床试验",
                        "受理"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-05-20",
                "original_text": "贝达药业公告，泽弗利单抗注射液联合巴替利单抗注射液治疗晚期宫颈癌的药品临床试验申请获得受理。",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "泽弗利单抗",
                        "巴替利单抗",
                        "晚期宫颈癌",
                        "临床试验",
                        "受理"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-05-20",
                "original_text": "风险众多，益方生物能够IPO成功？",
                "features": {
                    "keywords": [
                        "益方生物",
                        "IPO",
                        "风险"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}